skip to primary navigationskip to content
 

03.06.16 Rick Livesey announces new spinout, Gen2

last modified Jun 07, 2016 11:54 AM
Gurdon Institute group leader Rick Livesey announces investment from the Dementia Discovery Fund into his new spinout company Gen2 Neuroscience Ltd, which aims to develop disease-modifying drugs for dementia.
03.06.16 Rick Livesey announces new spinout, Gen2

Dr Rick Livesey

Dementia Discovery Fund invests in Gen2 Neuroscience Ltd 

Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in dementia, thereby slowing disease progression. 

London and Boston, 3 June 2016 - The Dementia Discovery Fund, managed by SV Life Sciences, is an innovative global investment fund launched in October 2015 to develop disease modifying drugs for dementia, announces an investment in new drug discovery company Gen2 Neuroscience Ltd. Gen2 is a seed company engaged in the discovery and development of novel treatments for dementia targeting abnormal forms of the essential cellular protein tau. The company uses proprietary platforms (human diseased and healthy neurons generated from inducible stem cells derived from dementia patients) to identify and target pathological forms of tau, with the aim of developing novel drugs to these tau species. The development of such a novel anti-tau therapeutic intervention could make it possible to slow disease progression. 

Gen2 Neuroscience has a strong founding team led by Rick Livesey (CEO) from the University of Cambridge who brings a deep understanding of tau biology and the use of human stem cell systems for research in neurodegeneration. Mark Treherne PhD (CEO of Talisman, Ex-Pfizer, BioFocus, Senexis) is Chairman, and Emily Scraggs PhD (COO of Talisman, formerly RAND Corp, Viant Corp, Keane Inc) is COO. 

Carol Routledge, Venture Partner, said: DDF’s mission is to provide resources for world-leading scientists to pursue novel approaches to treating dementia. This investment in Gen2 and its scientific team is fully aligned with our mission.” 

Rick Livesey, Gen2 Neuroscience, CEO, added: The entire Gen2 team is excited to work with the DDF to accelerate the development of anti-tau therapeutics in dementia. The DDF team is providing valuable support at this key stage in the company’s development.”

 

[The above text is reproduced from a press release issued by Gen2 and the Dementia Discovery Fund.]

Studying development to understand disease

The Gurdon Institute is funded by the Wellcome Trust and Cancer Research UK to study the biology of development, and how normal growth and maintenance go wrong in cancer and other diseases.